TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prolongation of pregnancy until a favorable gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of SARS-CoV-2 infections
Endpoint domain: Adverse events/effects
Primary endpoint: Delirium screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients treated by GPC after ED referral
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of first reduction attempt success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of arrival to beginning of first reduction attempt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delay to obtain criteria of premature recovery after mastectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete radiographic resolution of walled-off necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fugl-Meyer Upper Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with Levitra treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Adverse Events or Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of bronchiectasis exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: WheezeRate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Free 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Attended ≥ 80% of Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Practiced Meditation ≥ 4 Days Per Week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Completed Assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Major and Clinically Relevant Non-major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first AF episode recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With a Response Within 10 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Bictegravir (Total)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Bictegravir (Free)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Bictegravir (Total)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Bictegravir (Free)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Bictegravir (Total)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Bictegravir (Free)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Concentration-Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative time on NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of Device-related or Procedure-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Patency of the Treated Area as Verified by CT Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Score Change- Sinonasal Outcome (SNOT) 20 Score Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: V-ADAS-cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: lipids and lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oocyte retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of patients who tolerated 70 degree head up tilt table test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who show evidence of dysautonomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who tolerated thermoregulatory sweat test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as Assessed by Number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Whose Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) Levels >3x Upper Limit of Normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Withdrawal Scores From Baseline After Receiving Placebo
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long term prognosis
Endpoint domain: Mortality/survival
Primary endpoint: Proportions of Participants Who Experienced Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability and reproducibility of subjective symptoms of myalgias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Methadone/Buprenorphine Dose to 0 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastric volume assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Electroencephalogram (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cartilage biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Boston Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tolerability of polypectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uracil levels (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dihydrouracil levels (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pH impedance probe results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in naloxone knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Questionnaire responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative rate of TRUE positive nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Trigger point pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MammoWave sensitivity (number of 'true positive' results)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients with Substantial Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of intrauterine fetal demise/intra-/postpartum fetal death
Endpoint domain: Mortality/survival
Primary endpoint: Number of traumatic incidents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cardiovascular incidents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients experiencing adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival at 6 (PFS-6) Month
Endpoint domain: Mortality/survival
Primary endpoint: Composite Response of Microbiological Eradication and Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With At Least 1-Point Improvement on the GCRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fecal Excretion of LY2940680 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary Excretion of LY2940680 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Adjusted Rate of Moderate/Severe COPD Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) with < 33% Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of subjects experiencing a DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma lutein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Zeaxanthin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peroxisome Biochemical Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: safety of V10153
Endpoint domain: Adverse events/effects
Primary endpoint: Antifungal Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Who Achieved a Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved an Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change and percent change in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patched-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frizzled-7 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Claudin-5 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of total ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of total ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insufficient velopharyngeal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meaningful responses to external commands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants That Were Appropriately Screened for Contraceptive Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants That Were Appropriately Counseled for DMPA Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Rate After Achieving Complete Abstinence
Endpoint domain: Mortality/survival
Primary endpoint: Safety of sublingual Flumazenil 0.4 mg
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Knee Society Score (KSS) Objective
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Knee Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New onset of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of in-home sensor monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quantity of diffuse myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: area below the curve (ABC 0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of at Least One Adenoma Per Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gouty Arthropathy Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Immediate Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants Reporting Solicited Local Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants With Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of priority assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with documented hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colonoscopy completion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects reaching criteria for discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with correct management care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Knowledge of Abuse
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PCR positivity in peripheral blood cell collections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of Sensor Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood flow in uterine and umbilical artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MLAD of 0.5 % bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inhibitory Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Behavior Rating Inventory of Executive Functioning (BRIEF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of average whole lung particle clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of Grade II or more dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Omega 3 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Illness perception (BIPQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health-related quality of life (RAND 36-item Health Survey 1.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Operative and post operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Need for second intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Tumour Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against Neisseria Meningitidis Serogroup C Using Baby Rabbit Completent (rSBA-MenC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient Health Questionnaire-9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive-Attentional Syndrome-1 (CAS-1)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of hypertensive disorders of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: detection of new areas of cerebral infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual analogue scale of pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Get Up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment rate/retention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of using TTNS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC (0-168)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Birth weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of Antipsychotic Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to get screened for cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Uterine Volume Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroid Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Consult Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in average number of minutes per week spent walking outdoors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Transition ratings of global perceived effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative changes of serum cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Analgetics used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in second operations (reexcision or mastectomy)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Days incarcerated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proliferation of colorectal cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of electroporation mediated intramuscular delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of electroporation mediated intramuscular delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Potentially Inappropriate Galenic Units
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Potentially Inappropriate Defined Daily Doses (DDDs) Per Average Resident and Per Day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Female Sexual Function Index Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain With Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in number of successful swallows
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to the risk factor intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Annual Rate of Change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients tested for CRC
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Excess Body Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes